LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

Search

Compugen Ltd

Atidarymo kaina

1.43 2.88

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.36

Max

1.46

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-161K

-7.3M

Pardavimai

-1M

1.3M

P/E

Sektoriaus vid.

60.333

35.733

Pelno marža

-584.089

Darbuotojai

74

EBITDA

1M

-7.4M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+494.41% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-11

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-958K

137M

Ankstesnė atidarymo kaina

-1.45

Ankstesnė uždarymo kaina

1.43

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-09-08 23:59; UTC

Įsigijimai, susijungimai, perėmimai

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

2025-09-08 22:02; UTC

Pagrindinės rinkos jėgos

Microsoft Signs $17.4 Billion AI Deal With Nebius

2025-09-08 17:01; UTC

Pagrindinės rinkos jėgos

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

2025-09-08 17:01; UTC

Pagrindinės rinkos jėgos

Tron Shares Rise After New Investment From Bravemorning

2025-09-08 16:14; UTC

Pagrindinės rinkos jėgos

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

2025-09-08 16:13; UTC

Pagrindinės rinkos jėgos

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

2025-09-08 23:12; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-08 23:12; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-09-08 23:12; UTC

Rinkos pokalbiai

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

2025-09-08 22:56; UTC

Rinkos pokalbiai

Worst May Be Over for New Zealand Retailers -- Market Talk

2025-09-08 22:23; UTC

Rinkos pokalbiai

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

2025-09-08 21:51; UTC

Rinkos pokalbiai

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

2025-09-08 21:47; UTC

Pagrindinės rinkos jėgos

Microsoft Signs $17.4B AI Deal With Nebius

2025-09-08 21:33; UTC

Įsigijimai, susijungimai, perėmimai

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

2025-09-08 21:20; UTC

Įsigijimai, susijungimai, perėmimai

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

2025-09-08 21:19; UTC

Įsigijimai, susijungimai, perėmimai

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

2025-09-08 21:18; UTC

Įsigijimai, susijungimai, perėmimai

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

2025-09-08 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2025-09-08 19:33; UTC

Rinkos pokalbiai

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

2025-09-08 19:22; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Settle Higher -- Market Talk

2025-09-08 19:02; UTC

Rinkos pokalbiai

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

2025-09-08 18:24; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-08 18:24; UTC

Rinkos pokalbiai

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

2025-09-08 17:29; UTC

Rinkos pokalbiai

Mexican Inflation Seen Little Changed in August -- Market Talk

2025-09-08 16:59; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

2025-09-08 16:36; UTC

Rinkos pokalbiai

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

2025-09-08 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-09-08 16:16; UTC

Uždarbis

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

2025-09-08 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-09-08 16:04; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

494.41% į viršų

12 mėnesių prognozė

Vidutinis 8.5 USD  494.41%

Aukščiausias 13 USD

Žemiausias 4 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

2

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

1.25 / 1.48Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
help-icon Live chat